Medigus to Present at the Innovation in Gastroenterology, 2017 Symposium: Vice President of Sales and Marketing, Yaron Silber...
January 03 2017 - 7:00AM
Medigus Ltd. (NASDAQ:MDGS) (TASE:MDGS), a medical device company
developing minimally invasive endosurgical tools and a leader in
direct visualization technology, announced today that Yaron
Silberman, PhD, Vice President of Sales and Marketing, will present
the Medigus Ultrasonic Surgical Endostapler, or MUSE™ system during
the Inventors Corner Session at the Innovation in Gastroenterology,
2017 Symposium, on January 4, 2017 at 5:50pm Israel time (UTC/GMT
+2 hours). The conference will take place at the Hilton Hotel, Tel
Aviv, Israel from January 4-6, 2017.
The Inventors Corner Session will provide a forum for physicians
and researchers to meet entrepreneurs, investors, hedge-fund
representatives and well-established pharmaceutical companies to
share innovations, daily clinical knowledge and cutting-edge
developments and the latest advances of clinical management in the
field of gastroenterology.
Silberman will present MUSE, a comprehensive device which
incorporates microvisual, ultrasonic and surgical stapling
capability. The device allows a single physician or surgeon to
perform fundoplication (stapling of the upper part of the stomach
to the lower esophageal sphincter) transorally (without incisions).
Since the device doesn’t require any incisions, patients generally
report greater comfort during the procedure and experience reduced
hospital stays by up to 50% over invasive fundoplication
procedures.
Innovation in Gastroenterology attendees can learn more about
the MUSE system by visiting www.medigus.com.
Innovation in Gastroenterology, 2017 Symposium This will be an
exclusive event where gastroenterologists, researchers, and the
pharmaceutical industry from all over the world can meet and learn
about novel emerging technologies as well as practical
gastroenterology and hepatology.
About MUSE™ The MUSE system is a leading technology in Natural
Orifice Endoscopic Surgery procedures. The single operator system
performs anterior partial fundoplication with standard surgical
staples in a less invasive way, compared to other surgical
procedures. Its intuitive endosurgical platform consists of a
single use flexible surgical endostapler, equipped with a
proprietary miniature camera, an ultrasonic sight and a range
finder. The endostapler, which resembles an endoscope, is designed
to be operated by a single user, includes a handle with controls,
an 80cm flexible shaft, a 5cm rigid section holding a cartridge
with 5 standard 4.8mm titanium surgical staples, a ratchet
controlled one-way articulating section, and a distal tip. The MUSE
system is FDA cleared and CE marked and has obtained the necessary
licenses to market the product in Canada and Israel.
About MedigusMedigus is a medical device company specializing in
developing minimally invasive endosurgical tools and highly
innovative imaging solutions. They are the pioneer developer of the
MUSE™ system, an FDA cleared and CE marked endoscopic device to
perform Transoral Fundoplication (TF) for the treatment of GERD
(gastroesophageal reflux disease), one of the most common chronic
conditions in the world. In 2016, the CMS established the Category
I CPT® Code of 43210 for TF procedures, such as the ones performed
with MUSE, which establishes reimbursement values for physicians
and hospitals. MUSE is gaining adoption in key markets around the
world – it is available in world-leading healthcare institutions in
the U.S., Europe and Israel. Medigus is also in the process of
obtaining regulatory clearance in China. Medigus is traded on the
Nasdaq Capital Market and the TASE (Tel-Aviv Stock Exchange). To
learn more about the company’s advanced technology, please visit
www.medigus.com or www.RefluxHelp.com.
This press release may contain statements that
are “Forward-Looking Statements,” which are based upon the
current estimates, assumptions and expectations of the company’s
management and its knowledge of the relevant market. The company
has tried, where possible, to identify such information and
statements by using words such as “anticipate,” “believe,”
“envision,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue,” “contemplate” and other similar
expressions and derivations thereof in connection with any
discussion of future events, trends or prospects or future
operating or financial performance, although not all
forward-looking statements contain these identifying words.
By their nature, Forward-Looking Statements involve uncertainties
which may cause future results of the company’s activity to differ
significantly from the content and implications of such statements.
Among the factors which may cause the actual results to differ from
the Forward-Looking Statements are changes in the target market and
the introduction of competitive products, our ability to secure
favorable reimbursement rates, regulatory, legislative and policy
changes, and clinical results. Other risk factors affecting the
company are discussed in detail in the Company's filings with the
Securities and Exchange Commission. Forward-Looking Statements are
pertinent only as of the date on which they are made, and the
company undertakes no obligation to update or revise any
Forward-Looking Statements, whether as a result of new information,
future developments or otherwise. Neither the company nor its
shareholders, officers and employees, shall be liable for any
action and the results of any action taken by any person based on
the information contained herein, including without limitation the
purchase or sale of company securities. Nothing in this press
release should be deemed to be medical or other advice of any
kind.
MEDIA CONTACT:
Chantal Beaudry
Lazar Partners Ltd.
212-867-1762
cbeaudry@lazarpartners.com
INVESTOR RELATIONS CONTACT (U.S.):
David Carey
Lazar Partners Ltd.
212-867-1762
dcarey@lazarpartners.com
INVESTOR RELATIONS CONTACT (Israel):
Iris Lubitch/ Noam Yellin
SmarTeam
972-3-6954333
Iris@Smartteam.co.il
Noam@Smartteam.co.il
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Sep 2023 to Sep 2024